Drug Trial Radar · NCT07445295
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
558
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Jun 30, 2028
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III, multi-center study to evaluate the efficacy and safety of chiauranib plus plus toripalimab, albumin-paclitaxel and gemcitabine as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma. The study includes two period: Run-in period and Randomized controlled period. The Run-in period is a single-arm, open-label study enrolling approximately 20 participants, who received the combination therapy of chiauranib plus toripalimab, albumin-paclitaxel and gemcitabine. The Randomized controlled period is a randomized, double-blind, parallel-controlled study enrolling approximately 538 participants, who are 1:1 randomly assigned to the experimental arm(chiauranib plus Toripalimab, albumin-paclitaxel and gemcitabine) or the control arm (Chiauranib placebo plus toripalimab placebo, albumin-paclitaxel and gemcitabine).
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ChiauranibDrug
50 mg, oral administration once daily
Toripalimab InjectionDrug
3mg/kg, maximum dose 240mg, administered intravenously on Days 1 and 15 of each 28-day cycle
Albumin-paclitaxel InjectionDrug
125 mg/m\^2, administered intravenously on Days 1, 8 and 15 of each 28-day cycle
Gemcitabine InjectionDrug
1000 mg/m\^2, administered intravenously on Days 1, 8 and 15 of each 28-day cycle
Chiauranib placeboDrug
50 mg, oral administration once daily
Toripalimab Injection placeboDrug
3mg/kg, maximum dose 240mg, administered intravenously on Days 1 and 15 of each 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse eventsTime frame: Run-in period.From the enrollment until 28 days after the last dose
- OSTime frame: Randomized controlled period. From the first dose to death or end of study, an average of 2 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.